Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159701899> ?p ?o ?g. }
- W3159701899 endingPage "2161" @default.
- W3159701899 startingPage "2161" @default.
- W3159701899 abstract "To better understand the molecular basis of resistance to azacitidine (AZA) therapy in myelodysplastic syndromes (MDS) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), we performed RNA sequencing on pre-treatment CD34+ hematopoietic stem/progenitor cells (HSPCs) isolated from 25 MDS/AML-MRC patients of the discovery cohort (10 AZA responders (RD), six stable disease, nine progressive disease (PD) during AZA therapy) and from eight controls. Eleven MDS/AML-MRC samples were also available for analysis of selected metabolites, along with 17 additional samples from an independent validation cohort. Except for two patients, the others did not carry isocitrate dehydrogenase (IDH)1/2 mutations. Transcriptional landscapes of the patients’ HSPCs were comparable to those published previously, including decreased signatures of active cell cycling and DNA damage response in PD compared to RD and controls. In addition, PD-derived HSPCs revealed repressed markers of the tricarboxylic acid cycle, with IDH2 among the top 50 downregulated genes in PD compared to RD. Decreased citrate plasma levels, downregulated expression of the (ATP)-citrate lyase and other transcriptional/metabolic networks indicate metabolism-driven histone modifications in PD HSPCs. Observed histone deacetylation is consistent with transcription-nonpermissive chromatin configuration and quiescence of PD HSPCs. This study highlights the complexity of the molecular network underlying response/resistance to hypomethylating agents." @default.
- W3159701899 created "2021-05-10" @default.
- W3159701899 creator A5003827072 @default.
- W3159701899 creator A5004854888 @default.
- W3159701899 creator A5013213241 @default.
- W3159701899 creator A5016067645 @default.
- W3159701899 creator A5020488064 @default.
- W3159701899 creator A5021071087 @default.
- W3159701899 creator A5035060999 @default.
- W3159701899 creator A5044809473 @default.
- W3159701899 creator A5058574596 @default.
- W3159701899 creator A5060622212 @default.
- W3159701899 creator A5068736593 @default.
- W3159701899 creator A5068872389 @default.
- W3159701899 creator A5080534438 @default.
- W3159701899 creator A5085743451 @default.
- W3159701899 creator A5085937659 @default.
- W3159701899 creator A5086626929 @default.
- W3159701899 creator A5090333475 @default.
- W3159701899 date "2021-04-30" @default.
- W3159701899 modified "2023-10-18" @default.
- W3159701899 title "Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients" @default.
- W3159701899 cites W1484293540 @default.
- W3159701899 cites W1497311409 @default.
- W3159701899 cites W1961515348 @default.
- W3159701899 cites W1964809738 @default.
- W3159701899 cites W1971273543 @default.
- W3159701899 cites W1973018894 @default.
- W3159701899 cites W2004821524 @default.
- W3159701899 cites W2015776863 @default.
- W3159701899 cites W2017671645 @default.
- W3159701899 cites W2021963759 @default.
- W3159701899 cites W2029595590 @default.
- W3159701899 cites W2043422368 @default.
- W3159701899 cites W2058097237 @default.
- W3159701899 cites W2061805762 @default.
- W3159701899 cites W2065087624 @default.
- W3159701899 cites W2069824481 @default.
- W3159701899 cites W2070263291 @default.
- W3159701899 cites W2086144679 @default.
- W3159701899 cites W2094807579 @default.
- W3159701899 cites W2095066915 @default.
- W3159701899 cites W2095286549 @default.
- W3159701899 cites W2103121534 @default.
- W3159701899 cites W2106462080 @default.
- W3159701899 cites W2106584820 @default.
- W3159701899 cites W2118771330 @default.
- W3159701899 cites W2129510594 @default.
- W3159701899 cites W2130410032 @default.
- W3159701899 cites W2132005991 @default.
- W3159701899 cites W2136905998 @default.
- W3159701899 cites W2141456042 @default.
- W3159701899 cites W2141997248 @default.
- W3159701899 cites W2144575277 @default.
- W3159701899 cites W2146493115 @default.
- W3159701899 cites W2146971593 @default.
- W3159701899 cites W2160730356 @default.
- W3159701899 cites W2168473428 @default.
- W3159701899 cites W2234445408 @default.
- W3159701899 cites W2304376138 @default.
- W3159701899 cites W2339658711 @default.
- W3159701899 cites W2408483783 @default.
- W3159701899 cites W2415515169 @default.
- W3159701899 cites W2462184373 @default.
- W3159701899 cites W2466510379 @default.
- W3159701899 cites W2509717357 @default.
- W3159701899 cites W2520593336 @default.
- W3159701899 cites W2554345186 @default.
- W3159701899 cites W2558560139 @default.
- W3159701899 cites W2585106732 @default.
- W3159701899 cites W2585283489 @default.
- W3159701899 cites W2585315580 @default.
- W3159701899 cites W2594476871 @default.
- W3159701899 cites W2611297475 @default.
- W3159701899 cites W2739087647 @default.
- W3159701899 cites W2742236947 @default.
- W3159701899 cites W2749646273 @default.
- W3159701899 cites W2765915913 @default.
- W3159701899 cites W2767172151 @default.
- W3159701899 cites W2768054923 @default.
- W3159701899 cites W2789081643 @default.
- W3159701899 cites W2792398247 @default.
- W3159701899 cites W2793457196 @default.
- W3159701899 cites W2804524416 @default.
- W3159701899 cites W2808639278 @default.
- W3159701899 cites W2886952897 @default.
- W3159701899 cites W2890562248 @default.
- W3159701899 cites W2892949113 @default.
- W3159701899 cites W2898284215 @default.
- W3159701899 cites W2899472109 @default.
- W3159701899 cites W2903026285 @default.
- W3159701899 cites W2904142799 @default.
- W3159701899 cites W2911369452 @default.
- W3159701899 cites W2911989837 @default.
- W3159701899 cites W2944244575 @default.
- W3159701899 cites W2966271115 @default.
- W3159701899 cites W2970304739 @default.
- W3159701899 cites W2972749034 @default.